Advertisement
Advertisement
IMVT
Immunovant, Inc. Common Stock
25.65
USDSponsored
+0.95
+3.83%
Apr 09, 15:59 UTC -4
Closed
Pre-Market
25.57
-0.08
-0.30%
IMVT Earnings Reports
Positive Surprise Ratio
IMVT beat 11 of 24 last estimates.
46%
Next Report
Date of Next Report
May 27, 2026
Estimate for Q4 26 (Revenue/ EPS)
--
/-$0.61
Implied change from Q3 26 (Revenue/ EPS)
--
/--
Implied change from Q4 25 (Revenue/ EPS)
--
/-4.69%
Immunovant, Inc. Common Stock earnings per share and revenue
On Feb 06, 2026, IMVT reported earnings of -0.61 USD per share (EPS) for Q3 26, beating the estimate of -0.72 USD, resulting in a 16.27% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +12.43% price change (close before vs. close after earnings).
Looking ahead to Q4 26, 17 analysts forecast an EPS of -0.61 USD, with revenue projected to reach -- USD, implying an increase of 0.00% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Pharvaris N.V. Ordinary Shares
Report Date
Apr 02, 2026 For Q4 25
Estimate
-$0.63
Actual
-$0.72
Surprise
-13.69%
Nanobiotix S.A. - ADR
Report Date
Mar 31, 2026 For Q4 25
Estimate
$0.55
Actual
-$0.39
Surprise
-170.16%
Innate Pharma S.A. ADS
Report Date
Apr 01, 2026 For Q1 26
Estimate
-$0.12
Actual
-$0.55
Surprise
-353.80%
MiNK Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.83
Actual
-$0.55
Surprise
+33.64%
Imunon, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$1.19
Actual
-$1.99
Surprise
-66.18%
Kairos Pharma, Ltd.
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.07
Surprise
-28.68%
Cadrenal Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$1.18
Actual
-$1.43
Surprise
-20.34%
Soligenix, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.57
Actual
-$0.28
Surprise
+50.98%
BioAtla, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$12.24
Actual
-$8.00
Surprise
+34.64%
Sunshine Biopharma Inc.
Report Date
Apr 03, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.54
Surprise
-96.08%
FAQ
What were Immunovant, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Immunovant, Inc. Common Stock reported EPS of -$0.61, beating estimates by 16.27%, and revenue of $0.00, 0% as expectations.
How did the market react to Immunovant, Inc. Common Stock's Q3 2026 earnings?
The stock price moved up 12.43%, changed from $24.06 before the earnings release to $27.05 the day after.
When is Immunovant, Inc. Common Stock expected to report next?
The next earning report is scheduled for May 27, 2026.
What are the forecasts for Immunovant, Inc. Common Stock's next earnings report?
Based on 17
analysts, Immunovant, Inc. Common Stock is expected to report EPS of -$0.61 and revenue of -- for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement